News

Articles

Pfizer may pay up to $630 million for access to Voyager’s novel AAV capsids in transgene research.

Pfizer Agrees to License Agreement with Voyager Therapeutics

Pfizer and BioNTech’s request would make them the first vaccine accessible to individuals under the age of 12.

Pfizer, BioNTech Request EUA for COVID-19 Vaccine in Children Aged 5-11

The agency received a marketing authorization application a monoclonal antibody treatment for COVID-19 patients.

Application for COVID-19 Treatment Submitted to EMA 

The agency’s human medicines committee approved an additional site in West Point, Pa. in the United States for the manufacture of Janssen’s COVID-19 vaccine. 

EMA Approves Manufacturing Site for Janssen COVID-19 Vaccine 

The collaboration between Sunovion, Sumitomo Dainippon, and Otsuka will focus on four compounds designed to treat neuropsychiatric health conditions.

Sunovion, Sumitomo Dainippon, and Otsuka Enter Development and Commercialization Collaboration

Merck and Ridgeback Biotherapeutics' oral antiviral medication reduced the risk of hospitalization or death from COVID-19 by 50% relative to placebo in a Phase III clinical study.

Merck and Ridgeback Biotherapeutics’ Oral Antiviral COVID-19 Treatment Reduces Risk of Hospitalization or Death by 50%

Takeda will use Selecta Bioscience’s ImmTOR platform to develop gene therapies for lysosomal storage disorders.

Selecta Biosciences and Takeda Announce Gene Therapy Platform Licensing Agreement

AstraZeneca’s acquisition of Caelum Biosciences gives them access to CAEL-101, a promising light chain amyloidosis treatment.

AstraZeneca Acquires Caelum Biosciences

Pure Psyence, Pure Extracts and Psyence’s joint venture company, will develop psilocybin-derived treatments.

Pure Extracts and Psyence Form Joint Venture Corporation Pure Psyence

Merck’s 11.5 billion acquisition of Acceleron gives them access to their lead therapeutic candidate, sotatercept.

Biopharma News